Prevalence and clinical correlates of chronic obstructive pulmonary disease in heart failure patients: a cross-sectional study in China.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL Frontiers in Medicine Pub Date : 2025-02-03 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1477388

Ailing Zhu, Manman Hu, Dehai Ge, Xiujian Zhang, Jinfeng Zhang, Yangchun Wang, Xin Yao, Junjun Liu

{"title":"Prevalence and clinical correlates of chronic obstructive pulmonary disease in heart failure patients: a cross-sectional study in China.","authors":"Ailing Zhu, Manman Hu, Dehai Ge, Xiujian Zhang, Jinfeng Zhang, Yangchun Wang, Xin Yao, Junjun Liu","doi":"10.3389/fmed.2025.1477388","DOIUrl":null,"url":null,"abstract":"Background: Despite chronic obstructive pulmonary disease's (COPD)'s prevalence in the general populace, its incidence in heart failure (HF) patients is understudied. This study aimed to assess COPD prevalence and clinical associations in Chinese HF patients.Methods: From the Chinese Heart Failure Study, demographic and clinical details of 2008 HF patients were analyzed. Divided into 233 COPD cases and 1775 non-COPD controls, a multivariable logistic regression identified factors linked to COPD onset in HF, with thorough examination of intergroup clinical differences.Results: The incidence of COPD in HF individuals was 11.60% (233/2008). The COPD subgroup featured a higher ratio of individuals over 60 and males, alongside lower systolic blood pressure (SBP), body mass index (BMI), higher Charlson Comorbidity Index (CCI) scores, and increased PaCO₂ levels (p < 0.05). Type II respiratory failure and right ventricular dysfunction (RVD) were more prevalent in the COPD subgroup (p < 0.001). Binary logistic regression, after adjustments, indicated positive associations between COPD and age over 60 (OR = 3.831, 95%CI: 1.085-13.526, p = 0.037), male sex (OR = 1.587, 95%CI: 1.032-2.441, p = 0.036), higher CCI (OR = 2.214, 95%CI: 1.796-2.729, p < 0.001), elevated PaCO2 (OR = 1.035, 95%CI: 1.015-1.055, p < 0.001), and RVD (OR = 0.605, 95%CI: 0.119-3.063, p = 0.544). Inversely, higher SBP (OR = 0.990, 95%CI: 0.982-0.998, p = 0.020) and log (triglycerides) (OR = 0.183, 95%CI: 0.064-0.552, p = 0.002) were negatively correlated with COPD in HF patients.Conclusion: In a large cohort of Chinese Heart Failure (HF) patients, our study revealed a notable COPD prevalence. Key risk factors included age, sex, elevated PaCO2, CCI score, and right heart failure, while higher SBP and triglyceride levels offered protection. These insights lay groundwork for probing disease mechanisms and therapeutic approaches.","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1477388"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831890/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1477388","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite chronic obstructive pulmonary disease's (COPD)'s prevalence in the general populace, its incidence in heart failure (HF) patients is understudied. This study aimed to assess COPD prevalence and clinical associations in Chinese HF patients.

Methods: From the Chinese Heart Failure Study, demographic and clinical details of 2008 HF patients were analyzed. Divided into 233 COPD cases and 1775 non-COPD controls, a multivariable logistic regression identified factors linked to COPD onset in HF, with thorough examination of intergroup clinical differences.

Results: The incidence of COPD in HF individuals was 11.60% (233/2008). The COPD subgroup featured a higher ratio of individuals over 60 and males, alongside lower systolic blood pressure (SBP), body mass index (BMI), higher Charlson Comorbidity Index (CCI) scores, and increased PaCO₂ levels (p < 0.05). Type II respiratory failure and right ventricular dysfunction (RVD) were more prevalent in the COPD subgroup (p < 0.001). Binary logistic regression, after adjustments, indicated positive associations between COPD and age over 60 (OR = 3.831, 95%CI: 1.085-13.526, p = 0.037), male sex (OR = 1.587, 95%CI: 1.032-2.441, p = 0.036), higher CCI (OR = 2.214, 95%CI: 1.796-2.729, p < 0.001), elevated PaCO₂ (OR = 1.035, 95%CI: 1.015-1.055, p < 0.001), and RVD (OR = 0.605, 95%CI: 0.119-3.063, p = 0.544). Inversely, higher SBP (OR = 0.990, 95%CI: 0.982-0.998, p = 0.020) and log (triglycerides) (OR = 0.183, 95%CI: 0.064-0.552, p = 0.002) were negatively correlated with COPD in HF patients.

Conclusion: In a large cohort of Chinese Heart Failure (HF) patients, our study revealed a notable COPD prevalence. Key risk factors included age, sex, elevated PaCO₂, CCI score, and right heart failure, while higher SBP and triglyceride levels offered protection. These insights lay groundwork for probing disease mechanisms and therapeutic approaches.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world